The Last Clean Snapshot: What the CDC's 2024 HIV Data Tells Us About What Comes Next

The Centers for Disease Control and Prevention (CDC) released its National HIV Prevention and Care Objectives: 2026 Update on May 18, 2026, presenting the most recent national picture of the U.S. HIV care continuum. Among the roughly 38,434 people aged 13 and older diagnosed with HIV in 2024, 83.1% were linked to care within one month. Among the 1,103,895 people living with diagnosed HIV at year-end 2024, 77% received some care, 56% were retained in care, and 69% achieved viral suppression. The data are provisional, reflecting reports through December 2025 with a standard 12-month reporting delay per National HIV Surveillance System protocols.

The CDC's own summary notes these data "highlight the need for continued efforts to meet national HIV prevention and care goals." That is the agency saying out loud what every advocate already knows. The 2024 numbers are the last clean snapshot before a converging set of federal and state policy decisions begins reshaping what the next continuum-of-care report will show.

Where the System Is Failing People

The CDC data identifies precisely where the care continuum loses people, and the disparities are not subtle.

At diagnosis, 7.8% of people received a stage 0 classification, the marker of very early detection, with the highest rates among people aged 13–24 (11.2%) and American Indian/Alaska Native people (14.1%). On the other end, 21.7% received a stage 3 (AIDS) classification at diagnosis, reflecting late-stage disease and missed testing opportunities. Late diagnoses were concentrated among people aged 65 and older (35.5%), Asian and Native Hawaiian/Pacific Islander people (25.6% each), and people with HIV attributed to heterosexual contact (25.1%).

Linkage to care within one month ran at 83.1% overall, lowest among Black/African American people (80.8%), people with HIV attributed to injection drug use (80.2%), and people living in the South at the time of diagnosis (81.5%).

The retention figures are where the system's structural fragility becomes most visible. Of people living with diagnosed HIV, 77.0% received some care during 2024, but only 56% met the threshold for retention. That 21-point gap is the difference between a single lab visit and the sustained engagement that produces viral suppression. Viral suppression itself reached 68.5% nationally, with the lowest rates among people with HIV attributed to injection drug use (57.2%), Native Hawaiian/Pacific Islander people (63.9%), people aged 65 and older (65.8%), residents of the Northeast (66.7%), and women (67.8%). Six-month viral suppression after diagnosis hit 71.1% overall, dropping to 57.9% among people with HIV attributed to injection drug use and 69.2% among people diagnosed in the South.

These are not statistical curiosities. The populations at the bottom of each chart are the same populations most exposed to the safety-net erosion now underway.

Reading the Baseline Correctly

Before drawing conclusions from these numbers, we have to be honest about what produced them. The 2024 data does not reflect a steady state. It reflects a system already absorbing serious strain.

AIDS Drug Assistance Programs (ADAPs) served 257,644 people in 2024 across 49 reporting jurisdictions, representing roughly 23% of all people living with diagnosed HIV in the United States. ADAPs achieved an 87% viral suppression rate among clients served, eighteen points above the national rate, within a client population where 65% live at or below 200% of the Federal Poverty Level. That suppression rate is what targeted public health infrastructure produces when it functions. It was also achieved while ADAPs absorbed a 30% surge in new enrollments during the post-COVID Medicaid unwinding, and while inflation-adjusted federal ADAP appropriations declined 31% since 2005.

The 2024 baseline is what an under-resourced safety net can deliver on its best day. The resources are about to thin further.

What's Already Moving

The policy environment shifting around these numbers is not theoretical. It is on the calendar.

Federal funding. The FY26 Labor, Health and Human Services appropriations bill, finalized in February 2026, rejected approximately $2 billion in proposed cuts and preserved Ryan White at $2.6 billion, the Ending the HIV Epidemic initiative at $165 million, and CDC HIV/Viral Hepatitis/STD/TB Prevention at $1.384 billion. The Minority HIV/AIDS Fund was cut by $4 million. As the American Academy of HIV Medicine noted, flat funding will not achieve the goals set out in the Ending the HIV Epidemic plan or address recent transmission outbreaks. A floor is not a plan.

State ADAP retrenchment. Twenty-three states (including DC) have implemented or are considering ADAP cost-containment measures per NASTAD data. Florida reduced ADAP eligibility from 400% to 130% of the Federal Poverty Level on March 1, 2026, and removed Biktarvy, which accounts for 52% of the U.S. antiretroviral market, from its formulary. State legislation in mid-March restored $31 million through HB 697, recovering eligibility for over 11,000 people, but the underlying fiscal pressure remains. Arkansas, Louisiana, and New Jersey report considering waiting lists, a measure not used in over a decade.

Coverage and housing. H.R. 1's Medicaid cuts and work requirements threaten coverage for 42% of Medicaid enrollees with HIV. Enhanced ACA premium tax credits expired, producing an estimated 114% premium increase for subsidized enrollees and benchmark premium increases of 26% nationally, with 33% in Florida and 35% in Texas. The President's FY27 budget proposed eliminating HOPWA, the Housing Opportunities for Persons with AIDS program, funded at $529 million in FY26. On May 20, 2026, the House Appropriations Committee released its FY27 Transportation, Housing and Urban Development bill flat-funding HOPWA at $529 million, a reversal from the House's prior posture. Holding the line against elimination matters. Flat funding also does not house anyone new in a year when rents and homelessness are both climbing.

Each disparity in the CDC data maps onto a population now losing safety-net protection. Northeast residents with the lowest viral suppression face mounting Medicaid pressure. Southern residents and Black people with the lowest linkage rates are losing ACA tax credits in states where premiums rose most. People with HIV attributed to injection drug use, who post the lowest suppression rates across every cut of the data, face continued federal funding restrictions on sterile syringes despite the public health evidence supporting harm reduction.

Tools Ahead of the Rails

The clinical pipeline is running well ahead of the delivery system. CROI 2026 confirmed the efficacy of twice-yearly injectable lenacapavir for PrEP at 0.07 per 100 person-years incidence in PURPOSE 1 and 0.11 in PURPOSE 2. The VOLITION study showed 85% of treatment-naive adults opted to switch from daily pills to bimonthly long-acting cabotegravir/rilpivirine, with 95% maintaining suppression. Yet injectable cabotegravir and lenacapavir represent just 2.9% and 0.9% of total PrEP use globally, and 38% of ADAPs report difficulty implementing long-acting injectables and provider-administered drugs. The populations falling furthest behind in the CDC data are the same populations least likely to access these options today.

Defending the Baseline

The 2024 data identifies what needs protecting. Specific action remains available to the actors with authority.

Congress should increase the federal ADAP earmark to reflect documented enrollment growth and pursue Ryan White HIV/AIDS Program reauthorization, lapsed since 2013. Congress should reinstate and make permanent the enhanced ACA premium tax credits and require safety-net impact assessments in future drug pricing legislation. Congress should preserve HOPWA at no less than $529 million through conference and final passage of FY27 THUD appropriations. State Medicaid programs and ADAPs should design formularies that follow federal HIV treatment guidelines and reject prior authorization and step therapy on antiretrovirals. The Department of Health and Human Services and CDC should protect community-led surveillance and demographic data collection. We cannot close gaps we refuse to measure. Payers and ADAPs should expand coverage for long-acting prevention and treatment options and remove administrative barriers that delay access.

The Numbers We Are Choosing

The 2027 continuum-of-care report will reflect decisions being made right now, in state capitals enforcing ADAP cuts, in Congress drafting FY27 appropriations, in the implementation of H.R. 1, in what data the federal government continues to collect. Ending the HIV Epidemic remains possible at every level of analysis. So does walking backward from 69% viral suppression. The CDC has published the map of who is most at risk. Every actor with policy authority can read it. What shows up in the 2027 release will reflect what they chose to do with that information.

ADAPs Work. Federal Policy Is Defunding Them on Accident.

NASTAD released its 2026 National Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Program (ADAP) Monitoring Project Annual Report this month, and the numbers tell two stories at once. In 2024, state and territorial ADAPs served 257,644 people living with HIV across 49 reporting jurisdictions, achieving an 87% viral suppression rate among clients served. That figure significantly outpaces the estimated 67% suppression rate among all people living with diagnosed HIV in the United States, and it was achieved within a population where 65% of clients live at or below 200% of the Federal Poverty Level (FPL). By any clinical measure, ADAPs are delivering.

The second story is fiscal. Drug rebates generated through the 340B Drug Pricing Program now constitute 52% of total ADAP budgets, dwarfing the federal ADAP earmark at just 29%. A $2.7 billion safety net serving nearly one-quarter of all people living with diagnosed HIV in the country is now majority-funded by a revenue source that multiple federal policy changes are actively eroding. And demand is about to surge.

The Unwinding as Stress Test

The post-COVID Medicaid unwinding that began in April 2023 showed us what happens when coverage shifts push low-income people living with HIV off their insurance. ADAPs absorbed a 30% increase in new client enrollments and an 11% increase in total enrollment compared to 2022. Across 40 jurisdictions with comparable data, prescription drug spending grew 17% in two years, from $1.31 billion to $1.54 billion. Some states faced localized shocks: Pennsylvania's drug costs rose 82%, Arizona's nearly tripled. A JAMA Health Forum study confirmed that more than 25 million people nationally had Medicaid terminated during unwinding, with coverage losses concentrated among younger, healthier adults most likely to fall out of care when coverage disappears.

The system held. But the unwinding was a stress test, not the main event.

The Rebate Dependency Trap

Congressional appropriations for RWHAP Part B totaled $1.41 billion in FY2024, with ADAP-specific funding essentially flat. States have bridged the gap through 340B rebate revenue. In FY2019, 73% of rebates were applied to ADAP budgets; by FY2024, that figure reached 86%. Programs are retaining nearly every rebate dollar generated, and it still barely meets demand.

The Inflation Reduction Act (IRA) creates an unintended problem here. Its Medicare Part D reforms cap annual out-of-pocket drug costs at $2,000 in 2025 and $2,100 in 2026, which genuinely benefits Medicare beneficiaries. But ADAPs generate "partial-pay rebates" on cost-sharing payments made on behalf of clients enrolled in Medicare Part D. Lower cost-sharing means lower rebate revenue. The IRA's Medicare Drug Price Negotiation Program is likely to further compress the pricing benchmarks driving rebate calculations. The third negotiation round, announced in January 2026, selected Biktarvy for negotiated pricing effective in 2028. Biktarvy is the most widely prescribed single-tablet HIV regimen in the country and cost Medicare approximately $3.9 billion for 101,000 beneficiaries in the most recent measurement period. A negotiated reduction in Biktarvy's Medicare price could directly lower the "best price" benchmark that determines ADAP rebate revenue on the very drug that anchors most clients' treatment.

Layer on the PBM reform provisions signed into law in February 2026 requiring 100% rebate pass-through in Medicare Part D starting in 2028, plus manufacturer restrictions on 340B contract pharmacies that 54% of ADAPs report are creating payment challenges, and the picture is clear: the revenue stream funding more than half the HIV safety net is being squeezed from multiple directions, all at once, and the pressure is increasing.

Each of these policies may have merit on its own terms. But none were designed with a safety net impact assessment in mind, and the cumulative downstream effect on ADAP financing is significant and remains unaddressed.

The Demand Surge

While revenue contracts, demand is set to spike. H.R. 1, signed July 4, 2025, enacts the largest Medicaid cuts in the program's history. The Congressional Budget Office (CBO) estimates $911 billion in federal Medicaid spending reductions over a decade. KFF notes that more than 10.3 million people are likely to lose Medicaid. A Center for American Progress analysis found the bill's approximately $1 trillion in Medicaid cuts is roughly matched by approximately $1 trillion in tax reductions directed to the top 1% of earners. The priorities embedded in that budget math deserve scrutiny, to put it mildly.

And then the enhanced ACA premium tax credits expired at the end of 2025 without extension. Approximately 22 million people received those credits last year, and the average recipient has seen premiums more than double. The Urban Institute estimates roughly 5 million people may drop coverage and go uninsured, with the impact falling disproportionately on Black and low-income communities in metro areas like Houston and Atlanta, per the Economic Policy Institute. When the CBPP tallies all coverage losses, the total reaches roughly 15 million people newly uninsured by 2034.

For people living with HIV, these numbers carry specific weight. Medicaid is the single largest source of coverage for adults living with HIV at an estimated 40%, with 42% of those enrollees qualifying through the ACA expansion pathway H.R. 1's work requirements directly target. People living with HIV also rely on ACA Marketplace plans at higher rates than the general population; at least 40,000 ADAP clients were enrolled in Marketplace plans as of 2023. KFF estimates the premium tax credit expiration alone will cost state ADAPs an estimated $83.7 million in additional premium costs, with ADAPs in non-expansion states facing the steepest increases. If ADAPs cannot absorb those costs, KFF outlines the consequences: reduced income eligibility, restricted formularies, increased utilization management, and the possible return of waiting lists for the first time since 2012.

We don't have to speculate about what this looks like. On January 8, 2026, the Florida Department of Health announced sweeping changes to its ADAP, effective March 1: slashing income eligibility from 400% FPL to 130% FPL, eliminating insurance premium assistance, and removing Biktarvy from the formulary. NASTAD estimates more than 16,000 people will lose ADAP coverage. Florida cited rising premiums and the premium tax credit expiration, yet has not released an ADAP budget in over a year and bypassed the stakeholder engagement required under federal Ryan White guidelines. Every structural vulnerability the NASTAD report identifies played out in a single state in a matter of weeks.

What We Should Be Doing

The NASTAD report warns that H.R. 1 and the premium tax credit expiration threaten to "unravel the coverage gains" it documents. ADAPs serve 23% of all people living with diagnosed HIV. The Ending the HIV Epidemic (EHE) initiative depends on sustained viral suppression, which depends on treatment access, which depends on these programs remaining solvent. The data demands specific action. Short of reversing the policies of H.R. 1 and actually insuring poor people as a just and moral society might choose to do, several targeted measures could prevent the worst outcomes.

Congress should increase the federal ADAP earmark to reflect documented enrollment growth and the surge H.R. 1 will drive, and pursue RWHAP reauthorization to replace the year-to-year appropriations the program has relied on since its authorization lapsed in 2013. Flat funding in the face of 30% enrollment growth is a policy choice with consequences measured in lives.

Congress should reinstate and make permanent the enhanced ACA premium tax credits. For people already navigating the social determinants of health that create barriers to care, losing insurance coverage removes one of the few reliable pathways to sustained treatment access and viral suppression. Future drug pricing legislation should include safety net impact assessments to identify and offset downstream revenue effects on programs like ADAPs before those effects become crises.

States need targeted investment in ADAP administrative infrastructure to manage the coming enrollment wave. 60% of ADAPs already report maintaining client eligibility as challenging and 38% report difficulties implementing long-acting injectables and provider-administered drugs. The 30% enrollment surge during unwinding stretched existing capacity. What H.R. 1 delivers will be larger and longer-lasting.

The 2026 NASTAD report documents a system that works. An 87% viral suppression rate among a low-income population, achieved through sophisticated fiscal management and a decades-long commitment to keeping people in care, is a public health accomplishment we should be protecting. The question is whether we will defend the infrastructure that makes it possible, or let it collapse under the weight of policy decisions that were never designed to account for it.